Annals of Oncology

News:

More money for cancer treatment requested in the UK
Ann Oncol 9: 1039.
[PDF] [Request Permissions]

Major cuts for Dutch research
Ann Oncol 9: 1039.
[PDF] [Request Permissions]

Brundtland sweeps through WHO
Ann Oncol 9: 1039-1040.
[PDF] [Request Permissions]

Formula 1, an ideal vector for smoking
Ann Oncol 9: 1040.
[PDF] [Request Permissions]

A replica of FECS in the US
Ann Oncol 9: 1040-1041.
[PDF] [Request Permissions]

New bill will render terminal care more difficult in the US?
Ann Oncol 9: 1041.
[PDF] [Request Permissions]

Allègre to upset science and education in France
Ann Oncol 9: 1041.
[PDF] [Request Permissions]

Awards, appointments
Ann Oncol 9: 1041-1042.
[PDF] [Request Permissions]

Perhaps not everyone knows that...
Ann Oncol 9: 1042-1043.
[PDF] [Request Permissions]

Book reviews:

R. Obrist

Book review
Ann Oncol 9: 1043.
[PDF] [Request Permissions]

C. Sternberg

Book review
Ann Oncol 9: 1044.
[PDF] [Request Permissions]

D. B. Geffen

Book review
Ann Oncol 9: 1142.
[PDF] [Request Permissions]

Editorial:

K. A. Gelmon

The fine points of end points: Phase II trials in lung cancer
Ann Oncol 9: 1045-1046.
[PDF] [Request Permissions]

Special articles:

E. A. Eisenhauer

Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism: The Michel Clavel lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16–19 June 1998
Ann Oncol 9: 1047-1052.
[PDF] [Request Permissions]

Review:

E. Raymond, S. G. Chaney, A. Taamma, and E. Cvitkovic

Oxaliplatin: A review of preclinical and clinical studies
Ann Oncol 9: 1053-1071.
[Abstract] [PDF] [Request Permissions]

Review on evidence-based cancer medicine:

R. A. Haward

Preparing guidelines and documented clinical policies
Ann Oncol 9: 1073-1078.
[PDF] [Request Permissions]

Original articles:

I. Sekine, K. Kubota, Y. Nishiwaki, Y. Sasaki, T. Tamura, and N. Saijo

Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer
Ann Oncol 9: 1079-1084.
[Abstract] [PDF] [Request Permissions]

E. E. Vokes, R. H. Ansari, G. A. Masters, P. C. Hoffman, A. Klepsch, M. J. Ratain, D. F. Sciortino, T. E. Lad, S. Krauss, P. A. S. Fishkin, and H. M. Golomb

A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer
Ann Oncol 9: 1085-1090.
[Abstract] [PDF] [Request Permissions]

B.van Wegberg, M. Bacchi, P. Heusser, S. Helwig, R. Schaad, E. von Rohr, J. Bernhard, C. Hurny, M. Castiglione, and Th. Cerny

The cognitive-spiritual dimension - an important addition to the assessment of quality of life: Validation of a questionnaire (SELT-M) in patients with advanced cancer
Ann Oncol 9: 1091-1096.
[Abstract] [PDF] [Request Permissions]

G. Zanetta, S. Rota, S. Chiari, C. Bonazzi, G. Bratina, V. Torri, and C. Mangioni

The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma: A multivariate analysis
Ann Oncol 9: 1097-1101.
[Abstract] [PDF] [Request Permissions]

M. Degardin, J. Oliveira, L. Geoffrois, F. Rolland, J. P. Armand, Ph. Bastit, J. Chauvergne, P. Fargeot, M. van Glabbeke, M. A. Lentz, . Tresca, J. Boudillet, P. Fumoleau, and P. Cappelaere

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Ann Oncol 9: 1103-1107.
[Abstract] [PDF] [Request Permissions]

I. Moullet, G. Salles, N. Ketterer, C. Dumontet, F. Bouafia, E.-M. Neidhart-Berard, C. Thieblemont, P. Felman, and B. Coiffier

Frequency and significance of anemia in non-Hodgkin's lymphoma patients
Ann Oncol 9: 1109-1115.
[Abstract] [PDF] [Request Permissions]

M. Bangerter, F. Moog, I. Buchmann, J. Kotzerke, M. Griesshammer, M. Hafner, K. Elsner, N. Frickhofen, S. N. Reske, and . Bergmann

Whole-body 2-[¹⁸F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
Ann Oncol 9: 1117-1122.
[Abstract] [PDF] [Request Permissions]

Clinical case:

L. C. Floren, M. F. Hebert, A. P. Venook, V. C. Jordan, A. Cisneros, and K. A. Somberg

Tamoxifen in liver disease: Potential exacerbation of hepatic dysfunction
Ann Oncol 9: 1123-1126.
[Abstract] [PDF] [Request Permissions]

Short reports:

N. Androulakis, C. Kouroussis, S. Kakolyris, S. Tzannes, E. Papadakis, C. Papadimitriou, A. Geroyianni, T. Georgopoulou, I. Dimopoulou, J. Souglakos, A. Kotsakis, N. Vardakis, D. Hatzidaki, and V. Georgoulias

Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study
Ann Oncol 9: 1127-1130.
[Abstract] [PDF] [Request Permissions]

A.A. Garcia, R.A. Kempf, M. Rogers, and F.M. Muggia

A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas
Ann Oncol 9: 1131-1133.
[Abstract] [PDF] [Request Permissions]

M. J. Kersten, T. J. Verduyn, P. Reiss, L. M. Evers, F. de Wolf, and M. H. J. van Oers

Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: Clinical outcome and effect on HIV-1 viral load
Ann Oncol 9: 1135-1138.
[Abstract] [PDF] [Request Permissions]

Letters to the editor:

D. Lüftner, B. Flath, C. Akrivakis, M. Schweigert, B. Prinz, H. G. Mergenthaler, P. E. Petrides, K. D. Wernecke, and K. Possinger

Dose-intensified weekly paclitaxel induces multiple nail disorders
Ann Oncol 9: 1139-1140.
[PDF] [Request Permissions]

M. Colleoni, L. Orlando, C. Robertson, F. Nolé, G. Peruzzotti, R. Cassano, E. Orvieto, G. Viale, and A. Goldhirsch

Assessment of response in primary chemotherapy for breast cancer
Ann Oncol 9: 1140-1141.
[PDF] [Request Permissions]

Corrigendum:

Corrigendum
Ann Oncol 9: 1143.
[PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.